Lisanti Capital Growth’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Lisanti Capital Growth’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-16,946	Closed	-$825K	–	150
2017 Q4	$825K	Buy	16,946 +4,945	+41%	+$250K	0.47%	82
2017 Q3	$648K	Sell	12,001 -28,335	-70%	-$1.66M	0.41%	89
2017 Q2	$2.27M	Buy	40,336 +8,996	+29%	+$360K	1.51%	18
2017 Q1	$1.23M	Buy	+31,340	New	+$998K	1.76%	11
2016 Q1	–	Sell	-21,598	Closed	-$1.11M	–	122
2015 Q4	$1.11M	Buy	21,598 +7,692	+55%	+$373K	1.17%	40
2015 Q3	$593K	Sell	13,906 -4,824	-26%	-$233K	0.53%	76
2015 Q2	$853K	Buy	18,730 +3,325	+22%	+$134K	0.62%	75
2015 Q1	$585K	Buy	+15,405	New	+$529K	0.33%	90

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Lisanti Capital Growth's PTLA Position: Q1 2018 in Review

Lisanti Capital Growth sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2018, closing a stake of 16,946 shares — an estimated $825K sold.

Lisanti Capital Growth first reported a position in PTLA in Q1 2015 and held it in 8 quarters. The position peaked at $2.27M in Q2 2017. 180 funds tracked by Wall St. Rank hold PTLA as of Q1 2018.

Lisanti Capital Growth reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Lisanti Capital Growth sold 16,946 Portola Pharmaceuticals, Inc. shares in Q1 2018, an estimated $825K.
Lisanti Capital Growth first reported a position in Portola Pharmaceuticals, Inc. in Q1 2015 and held it in 8 quarters.
Lisanti Capital Growth's Portola Pharmaceuticals, Inc. position peaked at $2.27M in Q2 2017.
180 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2018.

Based on Lisanti Capital Growth's 13F filing for Q1 2018, filed 15 May 2018.